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apoptosis/survival (M6.6) and inﬂammation (M4.6) modules.
We show an inverse relationship between HIV-speciﬁc responses
(production of IL-2, IL-13, IL-21, IFN-c, CD4 polyfunctionality,
i.e. production of at least two cytokines) and the peak of viral load
during ATI. Those cellular immune responses were positively
correlated to genes associated with T cell functional modules
(M4.1, M4.15) at w16 and negatively correlated to genes associ-
ated with inﬂammation (e.g. EGLIN1, H2AFY, LTBR). Speciﬁ-
cally, IL-21 secretion, that was associated with control of viral
replication, was negatively correlated to MFAP3 and TFNRSF1A
inﬂammatory genes.
Conclusion: Changes in gene expression proﬁle were associated
with vaccine-elicited cellular responses and viral rebound during
ATI. Integrated analysis led to identify DC vaccine signatures
likely correlated with a better control of HIV replication.
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Background: The recent RV144 trial showed*30% efﬁcacy. Al-
though the protection was modest, the trial indicated for the ﬁrst
time that a vaccine against HIV is possible. Immune correlate
analysis suggests that the observed protection was due to non-
neutralizing antibody responses. This efﬁcacymight be improved
if a vaccine could elicit broadly neutralizing antibodies (bNAbs).
Of particular interest for vaccine design are the potent VRC01-
class bNAbs targeting CD4 binding site on Env. Unfortunately, a
number of studies have demonstrated that recombinant Env
proteins do not bind germline-reverted VRC01 class Abs, indi-
cating that current vaccine strategies using recombinant Env are
unable to activate progenitor B cells that ultimately give rise to
VRC01 class Abs.
Methods:We developed reagents and experimental protocols to
express functional versions of the mature and germline VRC01
and NIH45–46 BCRs on the surface of B cells, and assays to
monitor B cell activation following the antigenic-engagement of
these BCRs.
Results: Although several recombinant Env proteins were capa-
ble of binding to and stimulating B cells expressing the mature
BCR forms, no such interactions were recorded with B cells ex-
pressing the germline BCR forms. However, we identiﬁed key
conserved glycosylation sites in the Loop D and V5 regions of a
Clade C Env that prevent the binding of the clonally related
germline NIH45–46 and germline VRC01 BCRs. Disruption of
these glycosylation sites resulted in nM binding afﬁnity to
germline BCRs and activation of the corresponding B cells.
Conclusion: Our study identiﬁes the earliest roadblock in the
elicitation of anti-CD4-BS bNAbs; the lack of engagement of the
germline BCR forms of ‘VRC01’ class antibodies by commonly
used HIV Env immunogens. Importantly, we have developed a
way to overcome this roadblock through the design of an HIV
Env that engages and activates B cells expressing the germline
BCR forms of ‘VRC01’ class antibodies.
OA02.02
Focusing Antibody Responses to Speciﬁc Protein Surfaces
Through Site-Selective Glycan Addition
T. Schiffner1, K. Leonavicius1, H. Schuster1, L. Kong1, R. Saliba1,
F. Wegmann1, P. Huang2, G.B. Stewart-Jones1,W.R. Schief3,
B.G. Davis1, and Q.J. Sattentau1
1University of Oxford, Oxford, United Kingdom (Great Britain);
2University of Washington, Seattle, WA, USA; 3IAVI Neutralizing
Antibody Center, La Jolla, CA, USA
Background: Viruses such as human immunodeﬁciency virus
type-1 (HIV-1) and inﬂuenza A virus display rapidly mutating or
non-neutralizing immunodominant epitopes on their viral gly-
coproteins to escape antibody-mediated neutralization.
Methods: Immunosilent glycoconjugates with terminal sialic acid
were added site-selectively to the model protein hen egg lyso-
zyme (HEL), mutant an HIV-1 gp120 or engineered gp120 outer
domain. Epitope mapping was subsequently performed on sera
from immunized mice.
Results: Glycoconjugate addition of HEL led to site-selective loss
of antibody binding to epitopes containing modiﬁcation sites
in vitro. Immunization with modiﬁed protein led to refocusing of
antibody responses from masked to unmasked epitopes in vivo.
Application of this sialic acid masking strategy to HIV antigens
led to loss of antibody recognition in masked regions whilst
maintaining antigenicity of the CD4 binding site which is a target
of broadly neutralizing antibodies.
Conclusion: Our masking strategy attaches relatively small gly-
coconjugates to properly folded proteins under mild conditions
with near 100% efﬁciency. This approach circumvents many of
the problems, such as improper folding and low occupancy, as-
sociated with masking strategies using mutational redistribution
of N-linked glycosylation sites. Thus, sialic acid glycoconjugate
masking should allow focused targeting of speciﬁc antigenic re-
gions for increased B cell recognition, improving vaccine antigen
design.
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Background: The ability to induce a potent and broadly neu-
tralizing antibody (bNAb) response following vaccination is
critical in developing an effective HIV-1 vaccine. This study de-
scribes the design and construction of three HIV-1 subtype C
South African (derived from founder virus sequences) and three
Indian (derived from circulating virus sequences) Env immuno-
gens, and their antigenicity and immunogenicity testing in the
presence or absence of liganded CD4, in rabbits.
Methods: Monomeric (gp120) and trimeric (gp140GCN4 + )
conformations for IN26191, IN25710, IN25925, ZACAP45, ZA-
CAP210 and ZA706010164 were expressed in mammalian cells.
Unliganded or 2dCD4 S60C liganded Env glycoproteins were
puriﬁed by lectin afﬁnity chromatography, followed by confor-
mation and complex puriﬁcation using size exclusion
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